Article
Synergistic Effect of Epigenetic Modulator Decitabine and Metformin in the Battle Against Gastric Cancer: A Potential Therapeutic Strategy
2025-09-11
Abstract excerpt
<title>Abstract</title> <p> The 5-year global survival rate of patients with gastric cancer (GC) is approximately 20%; however, 74% of these patients survived for up to 1 year with effective therapy. The anticancer effects of metformin, an antidiabetic agent, and 5-Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), a DNA methyltransferase inhibitor that leads to malignant cell differentiation and apoptosis, have been...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- a1f889c3-8b16-52a2-beee-78ec8adbfc70
- DOI
- 10.21203/rs.3.rs-7382082/v1
